Onozuka D, Hagihara A, Nishimura K, Kada A, Nakagawara J, Ogasawara K, Ono J, Shiokawa Y, Aruga T, Miyachi S, et al; J-ASPECT Study Collaborators. Prehospital antiplatelet use and functional status on ad- mission of patients with non-haemorrhagic moyamoya disease: a na- tionwide retrospective cohort study (J-ASPECT study). BMJ Open. 401. Zhao Y, Zhang Q, Zhang D, Zhao Y. Effect of aspirin in postoperative management of adult ischemic moyamoya disease. World Neurosurg. 402. Acker G, Goerdes S, Schneider UC, Schmiedek P, Czabanka M, Vajkoczy P. Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians. Eur J Neurol. 2015;22:1012 1017. doi: 403. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moy- amoya disease. J Neurol Neurosurg Psychiatry. 2008;79:900 904. doi: 404. Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52:245 266. doi: 10.2176/nmc.52.245 405. Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, Nakagawara J, Takahashi JC; JAM Trial Investigators. Effects of extracra- nial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke. 2014;45:1415 1421. 406. Kim DY, Son JP, Yeon JY, Kim GM, Kim JS, Hong SC, Bang OY. Infarct pattern and collateral status in adult moyamoya disease: a multimodal magnetic resonance imaging study. Stroke. 2017;48:111 116. doi: 407. Kraemer M, Berlit P, Diesner F, Khan N. What is the expert s option on an- tiplatelet therapy in moyamoya disease? Results of a worldwide survey. Eur J Neurol. 2012;19:163 167. doi: 10.1111/j.1468-1331.2011.03481.x 408. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, Coffey C, McClure LA, Szychowski JM, Conwit R, et al; SPS3 Investigators. 